1. Home
  2. RNG vs KNSA Comparison

RNG vs KNSA Comparison

Compare RNG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RingCentral Inc.

RNG

RingCentral Inc.

HOLD

Current Price

$40.13

Market Cap

3.5B

Sector

Technology

ML Signal

HOLD

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

HOLD

Current Price

$53.16

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNG
KNSA
Founded
1999
2015
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.5B
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
RNG
KNSA
Price
$40.13
$53.16
Analyst Decision
Hold
Strong Buy
Analyst Count
14
7
Target Price
$33.58
$60.86
AVG Volume (30 Days)
1.3M
795.8K
Earning Date
05-07-2026
04-28-2026
Dividend Yield
0.75%
N/A
EPS Growth
176.19
225.00
EPS
0.48
0.27
Revenue
$2,515,142,000.00
$677,564,000.00
Revenue This Year
$5.56
$37.48
Revenue Next Year
$4.56
$17.87
P/E Ratio
$83.65
$198.13
Revenue Growth
4.78
60.09
52 Week Low
$23.59
$25.71
52 Week High
$43.83
$54.31

Technical Indicators

Market Signals
Indicator
RNG
KNSA
Relative Strength Index (RSI) 55.41 69.49
Support Level $25.56 $40.67
Resistance Level $43.13 N/A
Average True Range (ATR) 2.07 2.24
MACD -0.00 0.97
Stochastic Oscillator 64.27 93.68

Price Performance

Historical Comparison
RNG
KNSA

About RNG RingCentral Inc.

RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Share on Social Networks: